The Doctors Company Acquires ProAssurance for $1.3 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
The Doctors Company announced that it has completed the acquisition of ProAssurance. The combined company will protect more than 200,000 healthcare professionals and organizations nationwide with assets of $12B. The Doctors Companyacquiredall outstanding shares of ProAssurance for $25.00 per share in cash, for a total value of approximately$1.3B. ProAssurance shareholders approved the transaction in June 2025. In connection with the closing of the acquisition, ProAssurance's common stock will be deregistered with the SEC and delisted with NYSE. Public trading of ProAssurance securities has ceased.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRA
About PRA
ProAssurance Corporation is a holding company for property and casualty insurance companies. The Company operates through three segments, which include Specialty Property and Casualty, Workers Compensation Insurance and Segregated Portfolio Cell Reinsurance. Its Specialty Property and Casualty segment focuses on medical professional liability insurance and medical technology liability insurance. Its Workers Compensation Insurance segment offers workers compensation products in 19 core states in the East, South and Midwest regions of the continental United States. Its Segregated Portfolio Cell Reinsurance segment focuses on Segregated portfolio cell (SPCs) at Inova Re and Eastern Re, its Cayman Islands SPC operations. The Company’s insurance subsidiaries provide medical professional liability insurance, liability insurance for medical technology and life sciences risks and workers compensation insurance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
The Doctors Company Completes Acquisition of ProAssurance
- Acquisition Finalized: The Doctors Company has completed the acquisition of ProAssurance for $25 per share in cash, totaling approximately $1.3 billion, which will enable the combined entity to protect over 200,000 healthcare professionals, significantly enhancing market position.
- Strategic Integration: ProAssurance will operate as a wholly owned subsidiary of The Doctors Company, with both organizations committed to delivering exceptional service and long-term stability in a complex healthcare landscape, thereby increasing client trust.
- Market Impact: This merger positions The Doctors Company as the largest provider of medical liability and specialty insurance in the U.S., with total assets reaching $12 billion and direct written premiums exceeding $2.5 billion, further solidifying its leadership in the healthcare insurance market.
- Shareholder Approval: ProAssurance shareholders approved the transaction in June 2025, marking a deep collaboration in the medical liability insurance sector, which is expected to drive future business growth and innovation.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Change: NETSTREIT Corp. will replace ProAssurance Corp. in the S&P SmallCap 600 Index effective June 29, 2026, which is expected to enhance NETSTREIT's market visibility and liquidity.
- Acquisition Context: ProAssurance is being acquired by The Doctors Company in a cash deal expected to close soon, which will impact ProAssurance's market positioning and future growth prospects.
- Market Impact: The inclusion of NETSTREIT may attract more investor attention, particularly in the real estate sector, and is anticipated to boost its stock price while strengthening its competitive position in the small-cap market.
- Importance of S&P Index: As the largest index provider globally, S&P Dow Jones Indices' changes significantly influence investor decisions and market trends, and NETSTREIT's addition will further solidify its position in investment products.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Component Change: S&P Dow Jones Indices announced that NETSTREIT will replace ProAssurance in the S&P SmallCap 600 Index on June 29, indicating a growing interest in small-cap REITs that may attract more investor attention.
- Acquisition Impact: ProAssurance is set to be acquired by The Doctors Company in an all-cash deal expected to close soon, which could affect ProAssurance's market performance and investor confidence.
- NETSTREIT Performance: NETSTREIT demonstrated strong performance in Q1, showcasing its growth potential as a retail REIT, further solidifying its position in the small-cap market.
- Market Dynamics: Small-cap REIT stocks showed divergence in May, with NETSTREIT topping the most-shorted list, reflecting mixed market sentiment regarding its future performance while indicating a rising interest in small-cap REITs among investors.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Change: NETSTREIT Corp. will replace ProAssurance Corp. in the S&P SmallCap 600 Index effective June 29, 2026, which is expected to enhance NETSTREIT's market visibility and attract investor interest.
- Acquisition Update: ProAssurance is being acquired by Doctors Company in a cash deal expected to close soon, which will impact ProAssurance's market position and future growth prospects.
- Market Impact: The inclusion of NETSTREIT may draw more investor attention to its stock, potentially driving up its share price, while also affecting the overall performance of the S&P SmallCap 600 Index.
- Industry Context: S&P Dow Jones Indices is one of the largest index providers globally, and NETSTREIT's inclusion further solidifies its representation in the real estate sector, reflecting ongoing market confidence in this industry.
See More
ProAssurance Receives Approval for Sale to Doctors Company
- Stock Price Increase: ProAssurance (PRO) shares rose by 2%, reflecting market optimism regarding its transaction with Doctors Company, indicating increased investor confidence in the company's future prospects.
- Regulatory Approval Progress: The company has received approval from Pennsylvania's insurance regulator, marking a significant step forward for the transaction, although it still awaits approval from California regulators, highlighting the complexity of the deal's completion.
- Transaction Value: The total value of the deal is $1.3 billion, equating to $25 per share in cash, indicating Doctors Company's commitment to ProAssurance and its intent to expand in the healthcare insurance market.
- Completion Timeline: ProAssurance reiterated its expectation to close the transaction by June 30, demonstrating confidence in the process while providing shareholders with a clear timeline for the deal's finalization.
See More
ProAssurance Q1 Earnings Report Analysis
- Earnings Miss: ProAssurance reported a Q1 GAAP EPS of $0.16, missing expectations by $0.09, indicating pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated revenue of $262.63 million, a 3.5% year-over-year decrease, although it beat market expectations by $1.95 million, the ongoing revenue decline poses challenges for future growth.
- Market Reaction Analysis: Given the earnings miss, the market may adopt a cautious stance towards ProAssurance's future performance, prompting investors to monitor the company's strategic adjustments and market responses closely.
- Financial Health Outlook: Despite a slight revenue beat, the persistent decline in profitability may lead to increased financing costs in capital markets, potentially impacting the company's long-term growth strategy.
See More
The Doctors Company Completes Acquisition of ProAssurance
- Acquisition Finalized: The Doctors Company has completed the acquisition of ProAssurance for $25 per share in cash, totaling approximately $1.3 billion, which will enable the combined entity to protect over 200,000 healthcare professionals, significantly enhancing market position.
- Strategic Integration: ProAssurance will operate as a wholly owned subsidiary of The Doctors Company, with both organizations committed to delivering exceptional service and long-term stability in a complex healthcare landscape, thereby increasing client trust.
- Market Impact: This merger positions The Doctors Company as the largest provider of medical liability and specialty insurance in the U.S., with total assets reaching $12 billion and direct written premiums exceeding $2.5 billion, further solidifying its leadership in the healthcare insurance market.
- Shareholder Approval: ProAssurance shareholders approved the transaction in June 2025, marking a deep collaboration in the medical liability insurance sector, which is expected to drive future business growth and innovation.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Change: NETSTREIT Corp. will replace ProAssurance Corp. in the S&P SmallCap 600 Index effective June 29, 2026, which is expected to enhance NETSTREIT's market visibility and liquidity.
- Acquisition Context: ProAssurance is being acquired by The Doctors Company in a cash deal expected to close soon, which will impact ProAssurance's market positioning and future growth prospects.
- Market Impact: The inclusion of NETSTREIT may attract more investor attention, particularly in the real estate sector, and is anticipated to boost its stock price while strengthening its competitive position in the small-cap market.
- Importance of S&P Index: As the largest index provider globally, S&P Dow Jones Indices' changes significantly influence investor decisions and market trends, and NETSTREIT's addition will further solidify its position in investment products.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Component Change: S&P Dow Jones Indices announced that NETSTREIT will replace ProAssurance in the S&P SmallCap 600 Index on June 29, indicating a growing interest in small-cap REITs that may attract more investor attention.
- Acquisition Impact: ProAssurance is set to be acquired by The Doctors Company in an all-cash deal expected to close soon, which could affect ProAssurance's market performance and investor confidence.
- NETSTREIT Performance: NETSTREIT demonstrated strong performance in Q1, showcasing its growth potential as a retail REIT, further solidifying its position in the small-cap market.
- Market Dynamics: Small-cap REIT stocks showed divergence in May, with NETSTREIT topping the most-shorted list, reflecting mixed market sentiment regarding its future performance while indicating a rising interest in small-cap REITs among investors.
See More
NETSTREIT to Replace ProAssurance in S&P SmallCap 600 Index
- Index Change: NETSTREIT Corp. will replace ProAssurance Corp. in the S&P SmallCap 600 Index effective June 29, 2026, which is expected to enhance NETSTREIT's market visibility and attract investor interest.
- Acquisition Update: ProAssurance is being acquired by Doctors Company in a cash deal expected to close soon, which will impact ProAssurance's market position and future growth prospects.
- Market Impact: The inclusion of NETSTREIT may draw more investor attention to its stock, potentially driving up its share price, while also affecting the overall performance of the S&P SmallCap 600 Index.
- Industry Context: S&P Dow Jones Indices is one of the largest index providers globally, and NETSTREIT's inclusion further solidifies its representation in the real estate sector, reflecting ongoing market confidence in this industry.
See More
ProAssurance Receives Approval for Sale to Doctors Company
- Stock Price Increase: ProAssurance (PRO) shares rose by 2%, reflecting market optimism regarding its transaction with Doctors Company, indicating increased investor confidence in the company's future prospects.
- Regulatory Approval Progress: The company has received approval from Pennsylvania's insurance regulator, marking a significant step forward for the transaction, although it still awaits approval from California regulators, highlighting the complexity of the deal's completion.
- Transaction Value: The total value of the deal is $1.3 billion, equating to $25 per share in cash, indicating Doctors Company's commitment to ProAssurance and its intent to expand in the healthcare insurance market.
- Completion Timeline: ProAssurance reiterated its expectation to close the transaction by June 30, demonstrating confidence in the process while providing shareholders with a clear timeline for the deal's finalization.
See More
ProAssurance Q1 Earnings Report Analysis
- Earnings Miss: ProAssurance reported a Q1 GAAP EPS of $0.16, missing expectations by $0.09, indicating pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated revenue of $262.63 million, a 3.5% year-over-year decrease, although it beat market expectations by $1.95 million, the ongoing revenue decline poses challenges for future growth.
- Market Reaction Analysis: Given the earnings miss, the market may adopt a cautious stance towards ProAssurance's future performance, prompting investors to monitor the company's strategic adjustments and market responses closely.
- Financial Health Outlook: Despite a slight revenue beat, the persistent decline in profitability may lead to increased financing costs in capital markets, potentially impacting the company's long-term growth strategy.
See More
